First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
Subscribe To Our Newsletter & Stay Updated
